Foresite Capital Management VI LLC
Position in NERV — Minerva Neurosciences, Inc.
CIK 2013341
WEST HOLLYWOOD, CA
Position in NERV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$11,969,265
New position
Shares Held
1,986,600
first reported quarter
Ownership
4.26%
of shares outstanding
% of Portfolio
2.60%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Foresite Capital Management VI LLC holds $451,772,717 across 16 Biotechnology names. NERV ranks #9 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CGON |
CG Oncology, Inc.
|
2,221,474 | $150,349,360 | |
| 2 | ALMS |
Alumis Inc.
|
4,247,670 | $93,576,170 | |
| 3 | CNTA |
Centessa Pharmaceuticals plc
|
1,364,019 | $54,178,834 | |
| 4 | CRVS |
Corvus Pharmaceuticals, Inc.
|
1,831,233 | $26,790,938 | |
| 5 | DNLI |
Denali Therapeutics Inc.
|
1,209,971 | $23,231,443 | |
| 6 | AGIO |
Agios Pharmaceuticals, Inc.
|
525,000 | $17,760,750 | |
| 7 | VSTM |
Verastem, Inc.
|
3,146,631 | $16,677,144 | |
| 8 | KYMR |
Kymera Therapeutics, Inc.
|
146,332 | $12,187,992 |
All Filings in NERV
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,969,265 | 1,986,600 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||